These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38629963)

  • 1. Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy.
    Iwase T; Cohen EN; Gao H; Alexander A; Kai M; Chiv V; Wang X; Krishnamurthy S; Liu D; Shen Y; Kida K; Reuben A; Layman RM; Ramirez DL; Tripathy D; Moulder SL; Yam C; Valero V; Lim B; Reuben JM; Ueno NT
    Clin Cancer Res; 2024 Jun; 30(11):2424-2432. PubMed ID: 38629963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
    Schmid P; Cortes J; Dent R; McArthur H; Pusztai L; Kümmel S; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Im SA; Untch M; Fasching PA; Mouret-Reynier MA; Foukakis T; Ferreira M; Cardoso F; Zhou X; Karantza V; Tryfonidis K; Aktan G; O'Shaughnessy J;
    N Engl J Med; 2024 Nov; 391(21):1981-1991. PubMed ID: 39282906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detrimental Impact of Chemotherapy Dose Reduction or Discontinuation in Early Stage Triple-Negative Breast Cancer Treated With Pembrolizumab and Neoadjuvant Chemotherapy: A Multicenter Experience.
    Krishnan J; Patel A; Roy AM; Alharbi M; Kapoor A; Yao S; Khoury T; Hong CC; Held N; Chakraborty A; Kaliniski P; Salman A; Catalfamo K; Attwood K; Kirtani V; Shaikh SS; Chaudhary LN; Gandhi S
    Clin Breast Cancer; 2024 Dec; 24(8):e701-e711.e2. PubMed ID: 39198116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.
    Magbanua MJM; Ahmed Z; Sayaman RW; Brown Swigart L; Hirst GL; Yau C; Wolf DM; Li W; Delson AL; Perlmutter J; Pohlmann P; Symmans WF; Yee D; Hylton NM; Esserman LJ; DeMichele AM; Rugo HS; van 't Veer LJ
    Clin Cancer Res; 2024 Jun; 30(11):2444-2451. PubMed ID: 38470545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Efficacy of Avelumab Maintenance Therapy Versus Continued Chemotherapy Followed by Pembrolizumab in Metastatic Urothelial Carcinoma With No Progression After 4 Cycles of Chemotherapy: A Retrospective Study Using Propensity Score Matching.
    Kobayashi K; Matsumoto H; Sakano S; Yamamoto M; Tsuchida M; Tei Y; Nagao K; Oba K; Kitahara S; Yano S; Yoshihiro S; Yamamoto Y; Ohmi C; Komatsu H; Misumi T; Akao J; Shiraishi K
    Clin Genitourin Cancer; 2024 Dec; 22(6):102212. PubMed ID: 39270620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer.
    Harding JJ; Fan J; Oh DY; Choi HJ; Kim JW; Chang HM; Bao L; Sun HC; Macarulla T; Xie F; Metges JP; Ying J; Bridgewater J; Lee MA; Tejani MA; Chen EY; Kim DU; Wasan H; Ducreux M; Bao Y; Lindsey S; Bachini M; Morement H; Boyken L; Ma J; Garfin P; Pant S;
    Future Oncol; 2024; 20(31):2319-2329. PubMed ID: 39114870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen for adults with hepatocellular carcinoma.
    Naing C; Ni H; Aung HH
    Cochrane Database Syst Rev; 2024 Aug; 8(8):CD014869. PubMed ID: 39132750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilar monoclonal antibodies for cancer treatment in adults.
    Galvao TF; Livinalli A; Lopes LC; Zimmermann IR; Silva MT
    Cochrane Database Syst Rev; 2024 Nov; 11(11):CD013539. PubMed ID: 39607013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial.
    Mowery YM; Ballman KV; Hong AM; Schuetze SM; Wagner AJ; Monga V; Heise RS; Attia S; Choy E; Burgess MA; Bae S; Pryor DI; Van Tine BA; Tinoco G; Chmielowski B; Freeman C; Gronchi A; Meyer CF; Dickson MA; Hartner L; Davis LE; Powers BC; Moding EJ; Weinhold KJ; van de Rijn M; Brigman BE; Riedel RF; Kirsch DG
    Lancet; 2024 Nov; 404(10467):2053-2064. PubMed ID: 39547252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial.
    Heinzerling JH; Mileham KF; Robinson MM; Symanowski JT; Induru RR; Brouse GM; Corso CD; Prabhu RS; Haggstrom DE; Moeller BJ; Bobo WE; Fasola CE; Thakkar VV; Pal SE; Gregory JM; Norek SL; Begic XJ; Kesarwala AH; Burri SH; Simone CB
    Lancet Oncol; 2024 Nov; ():. PubMed ID: 39615497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer.
    Lum LG; Al-Kadhimi Z; Deol A; Kondadasula V; Schalk D; Tomashewski E; Steele P; Fields K; Giroux M; Liu Q; Flaherty L; Simon M; Thakur A
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34117114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of a Therapy Combining Sintilimab and Chemotherapy With Cryoablation in the First-Line Treatment of Advanced Nonsquamous Non-Small Cell Lung Cancer: Protocol for a Phase II, Pilot, Single-Arm, Single-Center Study.
    Gao Z; Teng J; Qiao R; Qian J; Pan F; Ma M; Lu J; Zhang B; Chu T; Zhong H
    JMIR Res Protoc; 2024 Nov; 13():e64950. PubMed ID: 39514267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study.
    Valenza C; Trapani D; Zagami P; Antonarelli G; Boscolo Bielo L; Nicolò E; Ribeiro JM; Guidi L; Reduzzi C; Spotti M; Adamoli L; Cortès J; Pistilli B; Tolaney SM; Ueno N; Layman RM; Cristofanilli M; Carey LA; Munzone E; Criscitiello C; Lynce F; Woodward WA; Curigliano G
    Eur J Cancer; 2024 Dec; 213():115097. PubMed ID: 39486164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
    Llovet JM; Kudo M; Merle P; Meyer T; Qin S; Ikeda M; Xu R; Edeline J; Ryoo BY; Ren Z; Masi G; Kwiatkowski M; Lim HY; Kim JH; Breder V; Kumada H; Cheng AL; Galle PR; Kaneko S; Wang A; Mody K; Dutcus C; Dubrovsky L; Siegel AB; Finn RS;
    Lancet Oncol; 2023 Dec; 24(12):1399-1410. PubMed ID: 38039993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic artery infusion chemotherapy combined with camrelizumab plus rivoceranib for hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter propensity score-matching analysis.
    Li Y; Guo J; Liu W; Pang H; Song Y; Wu S; Zhang F; Yan D; Chen J; An C; Li C
    Hepatol Int; 2024 Aug; 18(4):1286-1298. PubMed ID: 38717693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
    Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
    Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
    Bossi A; Foulon S; Maldonado X; Sargos P; MacDermott R; Kelly P; Fléchon A; Tombal B; Supiot S; Berthold D; Ronchin P; Kacso G; Salem N; Calabro F; Berdah JF; Hasbini A; Silva M; Boustani J; Ribault H; Fizazi K;
    Lancet; 2024 Nov; 404(10467):2065-2076. PubMed ID: 39580202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.
    Léna H; Greillier L; Cropet C; Bylicki O; Monnet I; Audigier-Valette C; Falchero L; Vergnenègre A; Demontrond P; Geier M; Guisier F; Hominal S; Locher C; Corre R; Chouaid C; Ricordel C;
    Lancet Respir Med; 2024 Oct; ():. PubMed ID: 39486424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.